Fei Cao

May 9, 2024 | onlinelibrary.wiley.com | Dingxin Liu |Fei Cao |Zhifeng Xu |Chunhua Zhao

Anthony Butler Department of Radiology, Centre for Bioengineering and Nanomedicine, University of Otago, Christchurch, 8011 New Zealand MARS Bioimaging Ltd., Christchurch, 8041 New Zealand Department of Physics and Astronomy, University of Canterbury, Christchurch, 8041 New ZealandSearch for more papers by this author

Mar 11, 2024 | nature.com | Di Wu |Yong Li |PengFei Xu |Fei Cao |Yaru Tian |Xinrui Zhang | +1 more

AbstractNeoadjuvant chemoimmunotherapy has emerged as a potential treatment option for resectable head and neck squamous cell carcinoma (HNSCC). In this single-arm phase II trial (NCT04826679), patients with resectable locally advanced HNSCC (T2‒T4, N0‒N3b, M0) received neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m2), and cisplatin (60 mg/m2) intravenously on day one of each three-week cycle for three cycles.

Oct 1, 2023 | onlinelibrary.wiley.com | Dingxin Liu |Fei Cao |Zhifeng Xu |Chunhua Zhao

Radioprotective agents hold clinical promises to counteract off-target adverse effects of radiation and benefit radiotherapeutic outcomes, yet the inability to control drug transport in human organs poses a leading limitation. Based upon a validated rank-based multigene signature model, we evaluate radiosensitivity indices of diverse normal organs as a genomic predictor of radiation susceptibility.

Jul 4, 2023 | mdpi.com | Fei Cao

Open AccessEditorialbyFei Cao 1,* and Yan Yang 2 1College of Mechanical and Electrical Engineering, Hohai University, Changzhou 213022, China2School of Energy and Power Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China*Author to whom correspondence should be addressed.